Identification of an irreversible PPARγ antagonist with potent anticancer activity

• Main Authors: Youyi Peng, Qiang Zhang, Robert M. Zielinski, Richard D. Howells, William J. Welsh
• Format: Article
• Language: English
• Published: Wiley 2020-12-01
• Series: Pharmacology Research & Perspectives
• Subjects: anticancer; irreversible antagonist; melanoma; PPARγ
• Online Access: https://doi.org/10.1002/prp2.693

Abstract Melanoma is responsible for most skin cancer deaths, and its incidence continues to rise year after year. Different treatment options have been developed for melanoma depending on the stage of the disease. Despite recent advances in immuno‐ and targeted therapies, advanced melanoma remains incurable and thus an urgent need persists for safe and more effective melanoma therapeutics. In this study, we demonstrate that a novel compound MM902 (3‐(3‐(bromomethyl)‐5‐(4‐(tert‐butyl) phenyl)‐1H‐1,2,4‐triazol‐1‐yl) phenol) exhibited potent efficacies in inhibiting the growth of different cancer cells, and suppressed tumor growth in a mouse xenograft model of malignant melanoma. Beginning with MM902 instead of specific targets, computational similarity‐ and docking‐based approaches were conducted to search for known anticancer drugs whose structural features match MM902 and whose pharmacological target would accommodate an irreversible inhibitor. Peroxisome proliferator‐activated receptor (PPAR) was computationally identified as one of the pharmacological targets and confirmed by in vitro biochemical assays. MM902 was shown to bind to PPARγ in an irreversible mode of action and to function as a selective antagonist for PPARγ over PPARα and PPARδ. It is hoped that MM902 will serve as a valuable research probe to study the functions of PPARγ in tumorigenesis and other pathological processes.